Maximum Grades By Making ready With RAC-US Dumps UPDATED 2023
Prepare RAC-US Exam Questions [2023] Recently Updated Questions
The final section of the RAPS RAC-US certification exam covers the ethical and professional responsibilities of regulatory professionals, including the importance of maintaining confidentiality, avoiding conflicts of interest, and adhering to ethical standards. This section also covers the various types of professional development opportunities that are available to regulatory professionals, such as training programs, conferences, and professional associations. Overall, the RAPS RAC-US certification exam is a rigorous and comprehensive test that is essential for regulatory professionals who are seeking to advance their careers in this field.
The Regulatory Affairs Certification (RAC) is a professional certification for regulatory professionals in the healthcare industry. It is a globally recognized credential that demonstrates a high level of expertise in regulatory affairs. The RAC certification is offered by Regulatory Affairs Professionals Society (RAPS), the largest global organization of regulatory professionals.
NEW QUESTION # 35
Which of the following BEST describes the purpose of the ICH?
- A. To protect and promote public health through the evaluation and supervision of safe, effective, and high-quality medicines for the ICH regions
- B. To provide scientific evaluation of applications for international marketing authorization for safe, effective, and high-quality medicines for the ICH regions
- C. To discuss and establish common guidelines for safe, effective, and high-quality medicines for the ICH regions
- D. To lobby for improved industry standards for the development of new safe, effective, and high-quality medicines for the ICH regions
Answer: C
NEW QUESTION # 36
A regulatory affairs professional has submitted a package for regulatory review.
According to the regulation, the regulatory authority will need to respond within 90 days of submission.
If there is no response after the deadline, what is the BEST approach?
- A. Contact the company legal representative in order to begin legal proceedings to enforce the regulatory authority's response time.
- B. Contact the regulatory authority, ask for clarification about the delay, and demand a decision be made regarding the submission.
- C. Contact the local political representative and ask for intervention with the regulatory authority to obtain a decision regarding the submission.
- D. Contact the regulatory authority, ask for clarification about the delay, and provide answers to any outstanding questions.
Answer: D
NEW QUESTION # 37
The requirements for document control are located in which of the following documents?
- A. WHO guidelines
- B. IEC 60601
- C. ICH guidelines
- D. ISO 13485
Answer: D
NEW QUESTION # 38
The safety database for an anti-hypertensive drug consists of the following:
* 461 patients exposed for three months
* 343 patients exposed for six months
* 112 patients exposed for nine months
* 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?
- A. 3.000 total patient exposures
- B. 200 patients for nine months
- C. 500 patients for three months
- D. 100 patients for 12 months
Answer: D
NEW QUESTION # 39
As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?
- A. Delay the start of product production.
- B. Inform the regulatory authorities.
- C. Correct the label text.
- D. Abort the product launch.
Answer: B
NEW QUESTION # 40
Which of the following BEST describes the content of the "Physical, Chemical, and
Pharmaceutical Properties and Formulation" section of an IB?
- A. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product
- B. A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation
- C. A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use
- D. A brief summary of relevant physical, chemical, and pharmaceutical properties:
instructions for storage and handling of the dosage form: and a description of the formulation
Answer: D
NEW QUESTION # 41
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. List of lECs or lRBs
- B. Randomization scheme and codes
- C. Protocol and protocol amendments
- D. Detailed CV of all investigators
Answer: D
NEW QUESTION # 42
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Deny the auditor access to the room and records due to confidentiality concerns.
- B. Allow the auditor accompanied access to the room to retrieve the records.
- C. Allow the auditor access to the room and records due to the current audit.
- D. Deny the auditor access to the room and retrieve only the requested records.
Answer: B
NEW QUESTION # 43
After submission to the regulatory authority, a substantial error was found in the application. In order to resolve this issue, what should be done FIRST?
- A. Contact the legal department and ask them how to proceed.
- B. Verify the procedure in the regulation for the corrections.
- C. Inform upper management immediately.
- D. Resubmit the entire package.
Answer: B
NEW QUESTION # 44
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on the part of the PI. What action should the sponsor take?
- A. Inform the institution that granted a medical license to the Pi.
- B. Terminate the PI and inform the regulatory authorities.
- C. Increase the frequency of monitoring visits.
- D. Send a letter of complaint to the Ethics Committee that approved the site.
Answer: B
NEW QUESTION # 45
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?
- A. Quality assurance
- B. Clinical affairs
- C. Quality improvement
- D. Regulatory agency
Answer: A
NEW QUESTION # 46
A company is developing a new line of products in an area that is new to the company.
What is the BEST approach?
- A. Ask the trade association representative to provide an overview of the new product area to the marketing team.
- B. Obtain competitor research and provide the information to the management team.
- C. Obtain regulatory documents and history and provide the information to R&D.
- D. Summarize regulatory documents and history and provide the information to the management team.
Answer: D
NEW QUESTION # 47
A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?
- A. The stability of the drug in all zone conditions
- B. The time frame in which the patent will expire
- C. International import and export regulations
- D. Doha Declaration in the TRIPS Agreement
Answer: A
NEW QUESTION # 48
Which term does NOT describe the same concept as the others?
- A. Biosimilars
- B. Subsequent entry biologics
- C. Follow-on protein products
- D. Monoclonal antibody
Answer: D
NEW QUESTION # 49
A regulatory affairs professional is asked to review and update regulatory affairs SOPs.
Which aspect of the SOP Is MOST important to consider?
- A. Revision history
- B. Expiration date
- C. Scope and level of detail
- D. Relevance to regulations
Answer: D
NEW QUESTION # 50
......
The RAC-US exam covers a broad range of topics, including regulatory strategy, product development, clinical trial design, quality assurance, and compliance. It is a comprehensive exam that requires candidates to demonstrate their understanding of the complex regulatory landscape and their ability to navigate it effectively. RAC-US exam is open to regulatory professionals with at least three years of experience in the field, and passing it is a significant achievement that can open up new career opportunities.
Give push to your success with RAC-US exam questions: https://www.exam4labs.com/RAC-US-practice-torrent.html
RAC-US 100% Guarantee Download RAC-US Exam PDF Q&A: https://drive.google.com/open?id=17cEg6V1VWLJZ3_wJLXbGMJti9hl_6rAP